查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1711274

2025年全球核子醫學市場報告

Therapeutic Nuclear Drug Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 200 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

預計未來幾年核醫市場規模將快速成長。到 2029 年，這一數字將成長至 38.6 億美元，複合年成長率為 14.7%。預測期內的成長歸因於向個性化醫療的轉變、對改善醫療保健基礎設施的需求不斷成長、老年人口的增加、診斷成像程序的增加以及個性化護理服務的興起。預測期內的主要趨勢包括基於奈米粒子的輸送系統、放射性核素治療的進步、混合成像系統、放射性藥物製造和α發射放射性藥物的發展以及機器學習和人工智慧的融合。

預計癌症發生率的上升將推動核子治療市場的成長。癌症的特徵是異常細胞不受控制地生長和擴散，由於檢測和診斷的改善、生活方式的選擇、環境暴露、遺傳易感性和其他因素，癌症變得越來越普遍。核子醫學在癌症治療中發揮著至關重要的作用，它透過提供有針對性的有效治療方法，幫助縮小腫瘤、緩解症狀並改善患者的生活品質。例如，2024年2月，總部位於瑞士的聯合國機構世界衛生組織（WHO）預測，2050年，全球新診斷癌症病例將超過3,500萬例，較2022年預計的2,000萬例增加77%。因此，癌症發生率的上升刺激了核子藥物市場的擴張。

核子治療市場的主要企業正在擴大建立策略夥伴關係，以加強其競爭地位。這些合作對於加強研發能力、加速新治療方法的商業化以及透過利用共用資源和專業知識改善來獲得創新治療方法的機會至關重要。例如，2022 年 7 月，德國軟體公司 DeepC 與美國人工智慧解決方案供應商 PAIRE 合作，共同推動核醫診斷領域的進步。此次合作旨在透過將 PAIRE 的 AI 解決方案 Pionus 整合到 DeepC 的 deepcOS 平台中來提高核醫學診斷的準確性和效率，從而增強 PET/ 電腦斷層掃描的解釋能力。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場 - 宏觀經濟情景，包括利率、感染疾病、地緣政治、新冠疫情、經濟復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 世界核子醫學PESTEL分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 最終用途產業分析
  • 全球核子醫學市場：成長率分析
  • 全球核能藥物市場表現：規模與成長，2019-2024
  • 全球核子醫學市場預測：2024-2029年及2034年規模與成長
  • 全球核能藥物總目標市場（TAM）

第6章市場區隔

  • 全球核子醫學市場：依類型、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 鐳223
  • 鎦177
  • 碘-131
  • 其他類型
  • 全球核能藥物市場：依通路、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 醫院
  • 門診手術中心（ASC）
  • 癌症研究所
  • 全球核子醫學市場：依應用、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 甲狀腺
  • 骨轉移
  • 淋巴瘤
  • 其他用途
  • 全球鐳-223核醫市場細分（依類型、績效及預測），2019-2024年，2024-2029年，2034年
  • 攝護腺癌適應症
  • 作用機制
  • 劑型
  • 全球核子治療藥物市場鎦177細分市場（按類型、績效及預測），2019-2024年，2024-2029年，2034年
  • 應用於神經內分泌腫瘤
  • 治療通訊協定
  • 聯合治療
  • 全球核子治療市場碘-131細分市場（依類型、績效及預測），2019-2024年、2024-2029年、2034年
  • 在甲狀腺癌的應用
  • 劑量和用法
  • 安全性和有效性
  • 全球核子治療市場，按類型細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 額外的治療同位素
  • 新的治療方法
  • 研發趨勢

第7章 區域和國家分析

  • 全球核子醫學市場：按地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球核子醫學市場：依國家、表現及預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章 德國市場

第18章 法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章競爭格局與公司概況

  • 核子治療市場：競爭格局
  • 核子治療市場：公司簡介
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • Ipsen SA Overview, Products and Services, Strategy and Financial Analysis
    • Jubilant DraxImage Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型創新企業

  • Mallinckrodt Pharmaceuticals PLC
  • The Bracco Group
  • Lantheus Medical Imaging Inc.
  • Piramal Group
  • Curium Pharmaceuticals
  • Yantai Dongcheng Pharmaceutical Group Co. Ltd.
  • Eckert & Ziegler
  • Telix Pharmaceuticals Limited
  • International Isotopes inc.
  • Orano SA
  • Q BioMed Inc.
  • Molecular Targeting Technologies Inc
  • Medi-Radiopharma Co. Ltd.
  • Actinium Pharmaceuticals
  • Fusion Pharmaceuticals

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章 高市場潛力國家、細分市場與策略

  • 2029年核能藥物市場：提供新機會的國家
  • 2029年核子治療市場：細分領域帶來新機會
  • 2029年核子治療市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第36章 附錄

簡介目錄
Product Code: r32299

Therapeutic nuclear drugs are medications that use radioactive materials to target and treat diseases, primarily cancer. These drugs employ targeted radiopharmaceuticals that bind to cancer cells and deliver a therapeutic dose of radiation directly to them, aiming to destroy the cancerous cells while minimizing damage to surrounding healthy tissue.

The main types of therapeutic nuclear drugs include radium-223, lutetium-177, iodine-131, and others. Radium-223, for example, is used mainly to treat prostate cancer that has metastasized to the bones. These drugs are distributed through various channels such as hospitals, ambulatory surgical centers, and cancer research institutes, and are utilized in applications like treating thyroid cancer, bone metastases, lymphoma, and other conditions.

The therapeutic nuclear drugs market research report is one of a series of new reports from The Business Research Company that provides therapeutic nuclear drugs market statistics, including the therapeutic nuclear drugs industry global market size, regional shares, competitors with a therapeutic nuclear drugs market share, detailed therapeutic nuclear drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the therapeutic nuclear drugs industry. This therapeutic nuclear drug research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The therapeutic nuclear drug market size has grown rapidly in recent years. It will grow from $1.94 $ billion in 2024 to $2.23 $ billion in 2025 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to increasing regulatory approvals, increasing use of patient-specific information, improving dosimetry techniques, increasing awareness of nuclear medicines and increasing investment in research and development activities.

The therapeutic nuclear drug market size is expected to see rapid growth in the next few years. It will grow to $3.86 $ billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to the shift towards personalized medicine, the rising demand for healthcare infrastructure improvements, the growing geriatric population, the growing number of diagnostic imaging procedures, and the rise of personalized care delivery. Major trends in the forecast period include nanoparticle-based delivery systems, advancements in radionuclide therapy, hybrid imaging systems, radiopharmaceutical manufacturing and development of alpha-emitting radiopharmaceuticals, and integration of machine learning and artificial intelligence.

The rising prevalence of cancer is expected to drive the growth of the therapeutic nuclear drug market. Cancer, characterized by the uncontrolled growth and spread of abnormal cells, is becoming more prevalent due to factors such as improved detection and diagnosis, lifestyle choices, environmental exposures, and genetic predisposition. Therapeutic nuclear drugs play a crucial role in cancer treatment by offering targeted, effective therapies that help reduce tumor size, alleviate symptoms, and improve patients' quality of life. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based UN agency, projected that over 35 million new cancer cases will be diagnosed by 2050, marking a 77% increase from the estimated 20 million cases in 2022. As a result, the growing prevalence of cancer is fueling the expansion of the therapeutic nuclear drug market.

Major companies in the therapeutic nuclear drug market are increasingly forming strategic partnerships to strengthen their competitive position. These collaborations are crucial for enhancing research and development capabilities, speeding up the commercialization of new therapies, and improving access to innovative treatments by leveraging shared resources and expertise. For example, in July 2022, DeepC, a Germany-based software company, partnered with PAIRE, a U.S.-based AI solutions provider, to advance nuclear medicine diagnostics. Through this partnership, they aim to improve the precision and efficiency of nuclear medicine diagnostics by integrating PAIRE's AI solution, Pionus, into DeepC's deepcOS platform, which enhances the interpretation of PET/CT scans.

In May 2024, Telix Pharmaceuticals Limited, an Australian biotechnology company, acquired QSAM Biosciences for an undisclosed amount. This acquisition aims to bolster Telix's therapeutic pipeline with the investigational drug Samarium-153-DOTMP, which targets bone metastases and osteosarcoma. QSAM Biosciences, a US-based biotech firm, specializes in developing next-generation nuclear therapeutic medicines.

Major companies operating in the therapeutic nuclear drug market are Bayer AG, Novartis International AG, Siemens Healthineers AG, Ipsen S.A., Jubilant DraxImage Inc., Mallinckrodt Pharmaceuticals PLC, The Bracco Group, Lantheus Medical Imaging Inc., Piramal Group, Curium Pharmaceuticals, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Eckert & Ziegler, Telix Pharmaceuticals Limited, International Isotopes inc., Orano SA, Q BioMed Inc., Molecular Targeting Technologies Inc, Medi-Radiopharma Co. Ltd., Actinium Pharmaceuticals, Fusion Pharmaceuticals

North America was the largest region in the therapeutic nuclear drug market in 2023. The regions covered in the therapeutic nuclear drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the therapeutic nuclear drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The therapeutic nuclear drug market consists of sales of yttrium-90, actinium-225, bismuth-213, therapeutic iodine-123, and copper-67. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Therapeutic Nuclear Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on therapeutic nuclear drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for therapeutic nuclear drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The therapeutic nuclear drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Radium-223; Lutetium-177; Iodine-131; Other Types
  • 2) By Distribution Channel: Hospitals; Ambulatory Surgical Centers (ASCs); Cancer Research Institutes
  • 3) By Application: Thyroid; Bone Metastasis; Lymphoma; Other Applications
  • Subsegments:
  • 1) Radium-223: Indications for prostate cancer; Mechanism of action; Dosage forms
  • 2) Lutetium-177: Applications in neuroendocrine tumors; Treatment protocols; Combination therapies
  • 3) Iodine-131: Use in thyroid cancer; Dosage and administration; Safety and efficacy
  • 4) Other Types: Additional therapeutic isotopes; Emerging treatments; Research and development trends
  • Companies Mentioned: Bayer AG; Novartis International AG; Siemens Healthineers AG; Ipsen S.A.; Jubilant DraxImage Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Therapeutic Nuclear Drug Market Characteristics

3. Therapeutic Nuclear Drug Market Trends And Strategies

4. Therapeutic Nuclear Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Therapeutic Nuclear Drug Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Therapeutic Nuclear Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Therapeutic Nuclear Drug Market Growth Rate Analysis
  • 5.4. Global Therapeutic Nuclear Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Therapeutic Nuclear Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Therapeutic Nuclear Drug Total Addressable Market (TAM)

6. Therapeutic Nuclear Drug Market Segmentation

  • 6.1. Global Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Radium-223
  • Lutetium-177
  • Iodine-131
  • Other Types
  • 6.2. Global Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Ambulatory Surgical Centers (ASCs)
  • Cancer Research Institutes
  • 6.3. Global Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Thyroid
  • Bone Metastasis
  • Lymphoma
  • Other Applications
  • 6.4. Global Therapeutic Nuclear Drug Market, Sub-Segmentation Of Radium-223, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Prostate Cancer Indications
  • Mechanism of Action
  • Dosage Forms
  • 6.5. Global Therapeutic Nuclear Drug Market, Sub-Segmentation Of Lutetium-177, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Applications in Neuroendocrine Tumors
  • Treatment Protocols
  • Combination Therapies
  • 6.6. Global Therapeutic Nuclear Drug Market, Sub-Segmentation Of Iodine-131, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Use in Thyroid Cancer
  • Dosage and Administration
  • Safety and Efficacy
  • 6.7. Global Therapeutic Nuclear Drug Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Additional Therapeutic Isotopes
  • Emerging Treatments
  • Research and Development Trends

7. Therapeutic Nuclear Drug Market Regional And Country Analysis

  • 7.1. Global Therapeutic Nuclear Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Therapeutic Nuclear Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Therapeutic Nuclear Drug Market

  • 8.1. Asia-Pacific Therapeutic Nuclear Drug Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Therapeutic Nuclear Drug Market

  • 9.1. China Therapeutic Nuclear Drug Market Overview
  • 9.2. China Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Therapeutic Nuclear Drug Market

  • 10.1. India Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Therapeutic Nuclear Drug Market

  • 11.1. Japan Therapeutic Nuclear Drug Market Overview
  • 11.2. Japan Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Therapeutic Nuclear Drug Market

  • 12.1. Australia Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Therapeutic Nuclear Drug Market

  • 13.1. Indonesia Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Therapeutic Nuclear Drug Market

  • 14.1. South Korea Therapeutic Nuclear Drug Market Overview
  • 14.2. South Korea Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Therapeutic Nuclear Drug Market

  • 15.1. Western Europe Therapeutic Nuclear Drug Market Overview
  • 15.2. Western Europe Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Therapeutic Nuclear Drug Market

  • 16.1. UK Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Therapeutic Nuclear Drug Market

  • 17.1. Germany Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Therapeutic Nuclear Drug Market

  • 18.1. France Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Therapeutic Nuclear Drug Market

  • 19.1. Italy Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Therapeutic Nuclear Drug Market

  • 20.1. Spain Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Therapeutic Nuclear Drug Market

  • 21.1. Eastern Europe Therapeutic Nuclear Drug Market Overview
  • 21.2. Eastern Europe Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Therapeutic Nuclear Drug Market

  • 22.1. Russia Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Therapeutic Nuclear Drug Market

  • 23.1. North America Therapeutic Nuclear Drug Market Overview
  • 23.2. North America Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Therapeutic Nuclear Drug Market

  • 24.1. USA Therapeutic Nuclear Drug Market Overview
  • 24.2. USA Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Therapeutic Nuclear Drug Market

  • 25.1. Canada Therapeutic Nuclear Drug Market Overview
  • 25.2. Canada Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Therapeutic Nuclear Drug Market

  • 26.1. South America Therapeutic Nuclear Drug Market Overview
  • 26.2. South America Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Therapeutic Nuclear Drug Market

  • 27.1. Brazil Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Therapeutic Nuclear Drug Market

  • 28.1. Middle East Therapeutic Nuclear Drug Market Overview
  • 28.2. Middle East Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Therapeutic Nuclear Drug Market

  • 29.1. Africa Therapeutic Nuclear Drug Market Overview
  • 29.2. Africa Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Therapeutic Nuclear Drug Market Competitive Landscape And Company Profiles

  • 30.1. Therapeutic Nuclear Drug Market Competitive Landscape
  • 30.2. Therapeutic Nuclear Drug Market Company Profiles
    • 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Ipsen S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Jubilant DraxImage Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Therapeutic Nuclear Drug Market Other Major And Innovative Companies

  • 31.1. Mallinckrodt Pharmaceuticals PLC
  • 31.2. The Bracco Group
  • 31.3. Lantheus Medical Imaging Inc.
  • 31.4. Piramal Group
  • 31.5. Curium Pharmaceuticals
  • 31.6. Yantai Dongcheng Pharmaceutical Group Co. Ltd.
  • 31.7. Eckert & Ziegler
  • 31.8. Telix Pharmaceuticals Limited
  • 31.9. International Isotopes inc.
  • 31.10. Orano SA
  • 31.11. Q BioMed Inc.
  • 31.12. Molecular Targeting Technologies Inc
  • 31.13. Medi-Radiopharma Co. Ltd.
  • 31.14. Actinium Pharmaceuticals
  • 31.15. Fusion Pharmaceuticals

32. Global Therapeutic Nuclear Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Therapeutic Nuclear Drug Market

34. Recent Developments In The Therapeutic Nuclear Drug Market

35. Therapeutic Nuclear Drug Market High Potential Countries, Segments and Strategies

  • 35.1 Therapeutic Nuclear Drug Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Therapeutic Nuclear Drug Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Therapeutic Nuclear Drug Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer